http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 16:20:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Grosswald+Ralph/26125756.html si-local-file:///var/storage/secattach/20260306/26125756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Grosswald+Ralph/26125756.html Fri, 06 Mar 2026 16:20:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Grosswald+Ralph/26125756.html si-local-file:///var/storage/secattach/20260306/26125756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Grosswald+Ralph/26125756.html Fri, 06 Mar 2026 16:20:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Walsh+Angela/26125735.html si-local-file:///var/storage/secattach/20260306/26125735.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Walsh+Angela/26125735.html Fri, 06 Mar 2026 16:19:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Walsh+Angela/26125735.html si-local-file:///var/storage/secattach/20260306/26125735.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Walsh+Angela/26125735.html Fri, 06 Mar 2026 16:19:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Gendreau+Roger+Michael/26125712.html si-local-file:///var/storage/secattach/20260306/26125712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Gendreau+Roger+Michael/26125712.html Fri, 06 Mar 2026 16:18:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Gendreau+Roger+Michael/26125712.html si-local-file:///var/storage/secattach/20260306/26125712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Gendreau+Roger+Michael/26125712.html Fri, 06 Mar 2026 16:18:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Duncan+Gregory+Scott/26125682.html si-local-file:///var/storage/secattach/20260306/26125682.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Duncan+Gregory+Scott/26125682.html Fri, 06 Mar 2026 16:17:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Duncan+Gregory+Scott/26125682.html si-local-file:///var/storage/secattach/20260306/26125682.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+05++Filed+by%3A+Duncan+Gregory+Scott/26125682.html Fri, 06 Mar 2026 16:17:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Dogwood+Therapeutics%2C+++++For%3A+Mar+11/26000010.html si-local-file:///var/storage/secattach/20260213/26000010.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Dogwood+Therapeutics%2C+++++For%3A+Mar+11/26000010.html Fri, 13 Feb 2026 16:06:00 +0000 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Dogwood+Therapeutics%2C+++++For%3A+Mar+11/26000010.html si-local-file:///var/storage/secattach/20260213/26000010.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Dogwood+Therapeutics%2C+++++For%3A+Mar+11/26000010.html Fri, 13 Feb 2026 16:06:00 +0000 DWTX O.00793356 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html <p align="center"> - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron<strong>®</strong> treatment to be well tolerated -<br/></p> <p align="justify">ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.</p> <p align="justify">“If the HALT-CINP study is http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+50%25+Enrollment+in+Ongoing+Halneuron%C2%AE+Phase+2b+Trial%2C+Top+Line+Results+Anticipated+in+Q3+2026/25927859.html Mon, 02 Feb 2026 08:30:00 +0000 A.60001765 DWTX O.00793356 O.20738543